INNATE PHARMA
-
EUR
(-)
- 15 min delayed data - Euronext Paris
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | IPH |
| ISIN: | FR0010331421 |
INNATE PHARMA news, videos and press releases
For more news please use our advanced search feature.
INNATE PHARMA - More news...
INNATE PHARMA - More news...
- 04/03/2025 - 05:00 Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
- 03/27/2025 - 06:00 Innate Pharma Reports Full Year 2024 Financial Results and Business Update
- 03/26/2025 - 06:00 Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
- 03/25/2025 - 06:00 Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
- 03/20/2025 - 06:00 Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
- 02/27/2025 - 06:00 Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
- 02/17/2025 - 06:02 Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
- 01/27/2025 - 06:00 Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
- 01/21/2025 - 06:00 Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
- 01/16/2025 - 06:00 Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
- 01/10/2025 - 06:00 Innate Pharma Announces Transformative Strategy to Accelerate Growth
- 12/20/2024 - 06:00 Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
- 12/09/2024 - 06:00 Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
- 12/06/2024 - 06:00 Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
- 12/03/2024 - 06:00 Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
- 11/20/2024 - 06:00 Innate Pharma Releases Its 2025 Financial Calendar
- 11/19/2024 - 06:00 Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
- 11/13/2024 - 06:00 Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
- 08/10/2023 - 05:00 Innate Pharma to Participate in Upcoming Investor Conference
- 08/10/2023 - 05:00 Innate Pharma to Participate in Upcoming Investor Conference
- 07/11/2023 - 05:00 First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
- 07/11/2023 - 05:00 First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
- 07/07/2023 - 05:00 Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
- 07/07/2023 - 05:00 Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
- 06/26/2023 - 05:00 Innate Pharma: First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
- 06/26/2023 - 05:00 First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
- 06/16/2023 - 05:00 Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
- 06/16/2023 - 05:00 Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
- 06/12/2023 - 05:00 Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
- 06/12/2023 - 05:00 Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
